CRLX101, a HIF-1α expression inhibitor, has completed a phase II trial in combination with bevacizumab, an antibody that targets VEGF, for the treatment of recurrent platinum-resistance ovarian, tubal, and primary peritoneal cancers and reduce tumor frequency and size [142,143]. This evidence concerns the gene HIF1A and neoplasm.